Fiona Marston, CEO
Absynth develops vaccines to prevent bacterial infections to address the challenge of antimicrobial resistance. Prevention of infections directly reduces the need for antibiotics and prophylactic vaccines have never induced resistance. Absynth’s vaccines target Staphylococcus aureus and Clostridium difficile, the cause of damage to health or death. Absynth is competitively placed with a suite of novel protein vaccine antigens that differ from and offer possible benefits over competitor products.